Rheumatology advances in practice · 2025
The comparative prevalence of comorbidities across rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Williams Jacob C, Southworth Joshua, Rogers Kira, Zhao Sizheng Steven
Аннотация
OBJECTIVES: Inflammatory arthritis (IA) is associated with a high comorbidity burden, yet few studies have compared comorbidities across IA subtypes. We aimed to compare 39 comorbidities across RA, PsA and axial spondyloarthritis (axSpA).
METHODS: We used UK Biobank data from over 500 000 participants aged 40-69 years. Baseline data for IA and comorbidities were identified via ICD-10 codes, primary care records and/or self-report. Analysis of variance (ANOVA) and chi-squared tests were used for group comparisons, and logistic regression was used to estimate adjusted odds ratios (ORs) for comorbidities in IA versus controls.
RESULTS: Of 230 055 participants (45.4% male; mean age 56.5 years), 1969 had RA, 606 PsA and 797 axSpA. Hypertension (prevalence 9.0-11.1%) and dyspepsia (5.3-7.9%) were more prevalent in IA than in controls. Individuals with RA had significantly higher odds of atherosclerotic cardiovascular diseases, including coronary artery disease (OR 2.1, 95% confidence interval [CI] 1.66, 2.67), stroke/transient ischaemic attack (TIA) (OR 1.78, 95% CI 1.09, 2.89) and peripheral vascular disease (OR 1.90, 95% CI 1.21, 2.99). Those with axSpA had higher odds of heart failure (OR 2.37, 95% CI 1.29, 4.34), atrial fibrillation (OR 1.59, 95% CI 1.03, 2.45) and epilepsy (OR 2.33, 95% CI 1.10, 4.94).
CONCLUSION: IA is linked to increased comorbidity prevalence, notably in cardiovascular, respiratory and gastrointestinal systems. The prevalence and odds of developing atherosclerotic cardiovascular disease were highest in those with RA. Individuals with axSpA have increased odds of developing epilepsy. These findings highlight the diverse comorbidity profiles across IA subtypes and support tailored management approaches.
METHODS: We used UK Biobank data from over 500 000 participants aged 40-69 years. Baseline data for IA and comorbidities were identified via ICD-10 codes, primary care records and/or self-report. Analysis of variance (ANOVA) and chi-squared tests were used for group comparisons, and logistic regression was used to estimate adjusted odds ratios (ORs) for comorbidities in IA versus controls.
RESULTS: Of 230 055 participants (45.4% male; mean age 56.5 years), 1969 had RA, 606 PsA and 797 axSpA. Hypertension (prevalence 9.0-11.1%) and dyspepsia (5.3-7.9%) were more prevalent in IA than in controls. Individuals with RA had significantly higher odds of atherosclerotic cardiovascular diseases, including coronary artery disease (OR 2.1, 95% confidence interval [CI] 1.66, 2.67), stroke/transient ischaemic attack (TIA) (OR 1.78, 95% CI 1.09, 2.89) and peripheral vascular disease (OR 1.90, 95% CI 1.21, 2.99). Those with axSpA had higher odds of heart failure (OR 2.37, 95% CI 1.29, 4.34), atrial fibrillation (OR 1.59, 95% CI 1.03, 2.45) and epilepsy (OR 2.33, 95% CI 1.10, 4.94).
CONCLUSION: IA is linked to increased comorbidity prevalence, notably in cardiovascular, respiratory and gastrointestinal systems. The prevalence and odds of developing atherosclerotic cardiovascular disease were highest in those with RA. Individuals with axSpA have increased odds of developing epilepsy. These findings highlight the diverse comorbidity profiles across IA subtypes and support tailored management approaches.